Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05345171 |
| Consolidated Lead Sponsor | Ultragenyx Pharmaceutical |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 37 participants (ACTUAL) |
| Registered Start Date | 2022-10-18 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| University of Colorado Anschutz Medical Campus | Aurora, CO | Open Hospital Dossier -> |
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | Open Hospital Dossier -> |
| University Hospitals Cleveland Medical Center | Cleveland, OH | Open Hospital Dossier -> |
| Hospital Italiano de Buenos Aires | Buenos Aires, Argentina | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Ultragenyx Pharmaceutical across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.